SLC6A3 and Parkinson disease: In the report, diabetic patients with PD being treated with DPP4 inhibitors had higher dopamine transporter availability in the putamina and a lower rate of levodopa-induced dyskinesia than that in diabetic patients with PD not taking DPP4 inhibitors.